AL 0180-0032

Stipend and Dates

Up to $8,700.

Note: All dates & times are tentative and may change.	Cohort 4A	Cohort 4B
Day -1 Admit	Jan 17, 2023 Tue	Jan 19, 2023 Thurs
Day 3 Discharge	Jan 20, 2023 Fri	Jan 22, 2023 Sun
Day 4 Outpatient Visit	Jan 21	Jan 23
Day 6 Outpatient Visit	Jan 23	Jan 25
Day 8 Outpatient Visit	Jan 25	Jan 27
Day 15 Outpatient Visit (a payment within 10 business days after completing this visit)	Feb 01	Feb 03
Day 22 Outpatient Visit	Feb 08	Feb 10
Day 29 Outpatient Visit	Feb 15	Feb 17
Day 43 Outpatient Visit (a payment within 10 business days after completing this visit)	Mar 01	Mar 03
Day 57 Outpatient Visit	Mar 15	Mar 17
Day 71 Outpatient Visit (a payment within 10 business days after completing this visit)	Mar 29	Mar 31

 

Click here to make an appointment for AL 0180-0032

Or call 210-225-5437 for more information

 

Study Criteria

Healthy Males and Females (Child bearing and non-child bearing allowed)

Age:  18-65

BMI:  18.5-29.9 – Must weigh at least 110 pounds

 

Study Information

Indication: The investigational drug is being developed as a possible treatment for a chronic skin condition.

Route of Administration: Subcutaneous

Washout from previous study: Participation in a clinical study and received treatment within 30 days prior to Day -1.

A woman is considered to be of childbearing potential unless she has been surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy or has been post-menopausal for at least 2 years and a man is considered to be potent unless he has been surgically sterilized (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate.

Males with partners of childbearing potential must be willing to use condoms in combination with a second effective method of contraception during the study.  Male subjects must continue to use contraception (condoms plus a second effective method) for 165 days following administration of the study drug. Male subjects must agree not to donate sperm during the study and for 165 days following administration of the study drug.

Women of childbearing (WOCBP) must have a negative serum pregnancy test result within 7 days prior to the first dosing plus a negative pregnancy test pre-dose prior to dosing and must be willing to use a highly effective form of contraception for the duration of the study and for at least 3 months after the last dose of study medication. Methods like periodic abstinence, post-ovulation procedures and withdrawal are not considered adequate.

 

Study Reminders

• 4 hours fasting is required for lab work (only water is allowed)
• If taking medications, bring them to your screening appointment (including prescription, over the counter, herbal supplements and vitamins)
• Bring a valid, non-expired photo ID with you when you attend your screening visit.  We accept a valid government issued identification card such as a driver's license, state issued ID card or passport.  You will be required to show this same photo ID at all study visits
• Arrive 30 minutes before your appointment to complete paper work.